MOLN SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 12, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 6, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 14, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 9, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 15, 2022

News

TYPE

HEADLINE

FILED AT

6-K

Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy and Announces Workforce Reduction

Oct 29, 2026

6-K

Molecular Partners Reports H1 2026 Financial Results and Pipeline Progress

Aug 25, 2026

6-K

Molecular Partners Announces First Patient Dosing in Phase 2 TACTIC Trial for Cholangiocarcinoma

Jul 20, 2026

6-K

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Jul 6, 2026

6-K

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

Jul 2, 2026

6-K

Molecular Partners Presents Phase 1/2a Trial Progress for DLL3-Targeting Radio-DARPin MP0712 at ASCO and SNMMI 2026

Jun 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

SHELF OFFERING | Shares amount: 3,642,988 | Share price: $5.49 | Offering amount: $20,000,000.00 | Bank: Leerink Partners, TD Cowen, LifeSci Capital

Oct 25, 2024

424B4

OFFERING | Shares amount: 3,000,000 | Share price: $21.25 | Offering amount: $63,750,000.00

Jun 16, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 24, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 25, 2025

F-3

April 2025 SHELFIAL REGISTRATION

Apr 11, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 26, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 28, 2023

F-3

SHELF | ATM | Offering amount: $300,000,000.00 EFFECTIVE

Jul 1, 2022

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (Filed by)

Jul 17, 2025

SCHEDULE 13G

SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)

May 2, 2025

SC 13D/A

BIOTECHNOLOGY VALUE FUND L P (Filed by)

Oct 29, 2024

SC 13D

BIOTECHNOLOGY VALUE FUND L P (Filed by)

Nov 20, 2023

SC 13G/A

BIOTECHNOLOGY VALUE FUND L P (Filed by)

Nov 7, 2023

SC 13G/A

BIOTECHNOLOGY VALUE FUND L P (Filed by)

Feb 14, 2023

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 25, 2025

CORRESP

Form CORRESP - Correspondence

Apr 22, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 21, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 13, 2022

CORRESP

Form CORRESP - Correspondence

Jul 8, 2022

LETTER

Form UPLOAD - SEC-generated letter

Jul 7, 2022

Molecular Partners AG MOLN · SEC Filings